NCT00923247 2018-11-29A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)National Institutes of Health Clinical Center (CC)Phase 1/2 Terminated22 enrolled 21 charts